Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Totally drug‐resistant tuberculosis and adjunct therapies

Parida, S. K., Axelsson‐Robertson, R., Rao, M. V., Singh, N., Master, I., Lutckii, A., Keshavjee, S., Andersson, J., Zumla, A., Maeurer, M.·2015·Journal of Internal Medicine

Abstract

The first cases of totally drug‐resistant (TDR) tuberculosis (TB) were reported in Italy 10 years ago; more recently, cases have also been reported in Iran, India and South Africa. Although there is no consensus on terminology, it is most commonly described as ‘resistance to all first‐ and second‐line drugs used to treat TB’. Mycobacterium tuberculosis (M.tb) acquires drug resistance mutations in a sequential fashion under suboptimal drug pressure due to monotherapy, inadequate dosing, treatment interruptions and drug interactions. The treatment of TDR‐TB includes antibiotics with disputed or minimal effectiveness against M.tb, and the fatality rate is high. Comorbidities such as diabetes and infection with human immunodeficiency virus further impact on TB treatment options and survival rates. Several new drug candidates with novel modes of action are under late‐stage clinical evaluation (e.g. delamanid, bedaquiline, SQ 109 and sutezolid). ‘Repurposed’ antibiotics have also recently been included in the treatment of extensively drug resistant TB. However, because of mutations in M.tb, drugs will not provide a cure for TB in the long term. Adjunct TB therapies, including therapeutic vaccines, vitamin supplementation and/or repurposing of drugs targeting biologically and clinically relevant molecular pathways, may achieve better clinical outcomes in combination with standard chemotherapy. Here, we review broader perspectives of drug resistance in TB and potential adjunct treatment options.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/joim.12264

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 169

Metadata

Authors
Parida, S. K., Axelsson‐Robertson, R., Rao, M. V., Singh, N., Master, I., Lutckii, A., Keshavjee, S., Andersson, J., Zumla, A., & Maeurer, M.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
2014-06-18
Volume
277
Issue
4
Pages
388-405
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
OpenAlex
W2117745534
Cited by
169
References
4
FWCI
12.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Totally drug‐resistant tuberculosis and adjunct therapies. https://app.cochat.ai/papers/10.1111/joim.12264
The paper
Parida, S. K., Axelsson‐Robertson, R., Rao, M. V., Singh, N., Master, I., Lutckii, A., Keshavjee, S., Andersson, J., Zumla, A., & Maeurer, M. (2015). Totally drug‐resistant tuberculosis and adjunct therapies. Journal of Internal Medicine. https://doi.org/10.1111/joim.12264

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.